ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,487.03
0.25%
Dow Jones
38,834.86
0.15%
US Dollar vs MXN
18.43794
0.02%
Brent Oil
84.515
-0.21%
Bitcoin
65,800.00
1.28%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. First Wave BioPharma Inc (FWBI)

  7. First Wave BioPharma Inc (FWBI) Noticias

FWBI First Wave BioPharma Inc

2.96
0.00 (0.00%)
19 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
First Wave BioPharma Inc FWBI NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 2.96 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.96
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
17/6/202416:23EDGAR2Form PRER14A - Preliminary Proxy Soliciting materials
14/6/202416:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/6/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
05/6/202416:15EDGAR2Form 8-K - Current report
31/5/202416:25EDGAR2Form S-3 - Registration statement under Securities Act of..
30/5/202416:32EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30/5/202416:18EDGAR2Form 8-K/A - Current report: [Amend]
16/5/202406:16EDGAR2Form 8-K - Current report
16/5/202406:00GLOBEFirst Wave BioPharma Changes Name to Entero Therapeutics
14/5/202416:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202416:26EDGAR2Form 8-K - Current report
13/5/202415:59EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/5/202406:55GLOBEFirst Wave BioPharma, Inc. to raise approximately $1.1..
09/5/202406:00GLOBEFirst Wave BioPharma and Celiac Journey to Host Nasdaq Event..
08/5/202416:16EDGAR2Form 8-K/A - Current report: [Amend]
24/4/202406:00GLOBEFirst Wave BioPharma Announces Invited Paper for Special..
17/4/202406:00GLOBEFirst Wave BioPharma CEO James Sapirstein to Present at the..
15/4/202406:00GLOBEFirst Wave BioPharma CEO James Sapirstein to Participate in..
18/3/202406:00GLOBEFirst Wave BioPharma Announces Two Abstracts on Celiac..
14/3/202405:00GLOBEFirst Wave BioPharma Announces Completion of Business..
05/3/202416:26EDGAR2Form 8-K - Current report
05/3/202406:00GLOBEFirst Wave BioPharma to Participate In ‘Fireside Chat’ at..
04/3/202416:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/3/202407:00GLOBEFirst Wave BioPharma, Inc. to Raise Approximately $4.0..
13/2/202406:00GLOBEFirst Wave BioPharma CEO to Present at the BIO CEO &..
23/1/202406:00GLOBEFirst Wave BioPharma to Present at the DealFlow MicroCap..
18/1/202415:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
17/1/202415:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202406:00GLOBEFirst Wave BioPharma CEO to Present at the Sequire Investor..
08/1/202416:14EDGAR2Form S-3 - Registration statement under Securities Act of..
04/1/202416:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202416:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202407:22EDGAR2Form 8-K - Current report
04/1/202405:00GLOBEFirst Wave BioPharma Chairman and CEO Issues Letter to..
03/1/202418:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/12/202311:21EDGAR2Form RW - Registration Withdrawal Request
27/12/202316:23EDGAR2Form 8-K - Current report
27/12/202310:55GLOBEFirst Wave BioPharma Announces Exercise of Warrants and..
27/12/202307:04EDGAR2Form S-1/A - General form for registration of securities..
27/12/202305:15EDGAR2Form 8-K - Current report
27/12/202305:00GLOBEFirst Wave BioPharma Announces Streamlining of Clinical..
18/12/202306:00EDGAR2Form 8-K - Current report
18/12/202305:00GLOBEFirst Wave BioPharma Announces Entry into Term Sheet for..
15/12/202320:48EDGAR2Form S-1/A - General form for registration of securities..
14/12/202308:15EDGAR2Form 8-K - Current report
14/12/202308:15GLOBEFirst Wave BioPharma Announces 1-for-20 Reverse Stock Split..
06/12/202306:00GLOBEFirst Wave BioPharma to Participate in BIO Partnering @JPM..
05/12/202306:00GLOBEFirst Wave BioPharma CEO James Sapirstein to Moderate Panel..
13/11/202315:20EDGAR2Form DEF 14A - Other definitive proxy statements
13/11/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Su Consulta Reciente

NASDAQ
FWBI
First Wave BioPharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados